LINCOLN, Mass., March 30, 2016 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug development, today announced that they will sponsor, moderate, and participate in Cancer Advance Boston 2016. Cancer Advance, being held April 4-5 at Harvard Medical School, brings together distinguished cancer experts from academia and industry, alongside the people who help turn discoveries into therapies for a high-energy, uniquely interactive meeting focused on the latest in cancer research.
Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath, will provide opening remarks as well as moderate a Novel Therapeutic Modalities Panel, which focuses on innovative approaches in cancer research. Dr. Burke brings a breadth of experience and appreciation for innovative approaches to this panel, as he has spent over a decade pioneering the application of mechanistic modeling in drug R&D in industry. As a testament to the impact that such innovative approaches have on cancer R&D, following his participation in Cancer Advance Boston, Dr. Burke will present Applied BioMath's recent work in immuno-oncology at the American Association of Cancer Research (AACR) Annual Meeting. Dr. Burke's poster will focus on quantitative systems pharmacology modeling and analysis, which provided biological insights into anti-PD-1 dosing and predicted optimal PD-1 x TIM-3 therapeutic properties for bispecifics and fixed dose combinations in immuno-oncology.
"I am privileged to be a part of such a distinguished meeting of cancer researchers. I look forward to sharing, discussing, and learning about recent advances in this important field."
Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath
About Applied BioMath
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug development, helps biotechnology and pharmaceutical companies answer complex, critical Go/No-go decisions in R&D. Applied BioMath leverages biology, proprietary technology, high-performance computing, and decades of industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, and the best path forward. Our involvement shortens project timelines, lowers cost, and increases the likelihood of a best-in-class drug. We provide clarity to complex situations, answer otherwise unanswerable questions, and our approach, when validated in the clinic, is 10x more accurate than traditional methodologies.
Applied BioMath and the Applied BioMath logo are trademarks of Applied BioMath, LLC.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/applied-biomath-llc-to-sponsor-and-moderate-at-cancer-advance-boston-2016-300243551.html
SOURCE Applied BioMath, LLC